Systemic autoimmune diseases are a heterogeneous group of disorders characterized by humoral and cell-mediated immune responses against various self-constituents. In specific cases, the heart and cardiovascular (CV) system are the primary organs targeted by the disease. On the other hand, several systemic autoimmune conditions are linked to enhanced atherosclerosis, with a consequently high CV morbidity and mortality rates. Persistent low-grade inflammation in the vascular wall is described to be important in the physiopathology of CV events. At first, inflammation is linked to endothelial dysfunction supporting the proliferation of vascular smooth muscle cells with subsequent vascular remodeling. Furthermore, the infiltration of innate and adaptive immune cells promotes a milieu of molecules that contributes to the perpetuation of inflammation itself. Although CV risk assessment should be part of routine care in patients with autoimmune diseases, no disease-specific models are currently available for this purpose. The main pillars of CV risk reduction are pharmacological and nonpharmacological management of cardiovascular CV risk factors, as well as tight control of disease activity.

This first volume represents the state-of-the-art in the field of cardiovascular disease and autoimmune rheumatic diseases. Systemic autoimmune diseases comprise a family of conditions that share common pathogenetic mechanisms as well as a multi-organ involvement including the heart. This volume has been subdivided into three parts. In the first part, the immune mechanisms involved in cardiac damage have been considered. The role of proinflammatory and regulatory cytokines in driving an autoimmune response to cardiac self-tissues has been analysed. Moreover, the prevalence, the clinical meaning and the hypothetical pathogenicity of a broad spectrum of organ and non-organ specific autoantibodies have been discussed in detail. In the second part of the volume, the role of humoral and innate immunity in promoting the development of atherosclerotic plaque has been extensively reviewed, along with the newly discovered anti-inflammatory properties of statins. These two parts of the volume deal with exciting aspects of this topic, suggesting a very close connection between heart diseases and immunology. Finally, in the third part, the cardiac manifestations observed in the major systemic autoimmune conditions have been comprehensively examined.This book yields an impressive body of well ordered information, highlighting key references and summarising the experience of a selected panel of distinguished physician-scientists actively involved in the field of cardiovascular disease and systemic autoimmunity.

The Heart in Systemic Autoimmune Diseases, Second Edition, provides an overview on our current understanding of major complications relating to the heart and autoimmune diseases. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations of these important comortbidities. Mortality in autoimmune diseases, in particular, rheumatoid arthritis and SLE, has increased when compared with the general population. This excess mortality is largely due to cardiovascular diseases (CVDs)-particularly those of atherosclerotic origin, such as ischemic heart disease-and is gaining recognition in all branches of medicine, from cardiology, to internal medicine, and from rheumatologists to orthopedics. - Presents an impressive body of well ordered information on the topic of cardiovascular diseases and their relationship to autoimmune illness - Highlights key references - Summarizes the experience of a selected panel of distinguished physician-scientists who are actively involved in the field of cardiovascular disease and systemic autoimmunity

The Lung in Autoimmune Diseases, Volume Seventeen identifies and describes the role of the lung in the most common systemic autoimmune diseases. From disease patterns, prognosis and risks to treatment, this book provides a comprehensive approach for the role of the lung in autoimmune diseases and the influence of autoimmune disease on the lung's functionality. In recent years, there is increasing knowledge in the field, including lung infection in early disease stages, mechanisms involved in lung damage, and new treatments. Recognition of lung involvement and implementation of some specific therapies is an important issue for clinicians dealing with systemic autoimmune diseases. - Provides a comprehensive review of the different patterns of pulmonary involvement in systemic autoimmune diseases - Describes new, targeted therapies for the treatment of systemic autoimmune diseases, including anti-fibrotics, biologics and vasodilators - Gives insights on the prognosis of patients suffering from systemic autoimmune diseases - Depicts better definitions of types of lung involvement in patients with an underlying systemic autoimmune disease

Many of the systemic autoimmune diseases seen in children are different from those seen in adults making them a special problem for physicians and scientists who care for the affected children and study their diseases. Benefiting both pediatric and adult rheumatologists, as well as physicians from other specialties, this volume covers the latest advances in pathogenesis and clinical management of common conditions seen in pediatric rheumatology practices.

The prevalence of autoimmune diseases and rheumatic conditions is constantly increasing. Autoimmune diseases affect approximately 7-10% of the population of the United States, while more than 50,000,000 American adults suffer from some type of arthritis. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases examines the complex mechanisms relating to cardiac diseases from a pathophysiological and clinical point of view. Autoimmune rheumatic diseases can affect the coronary vessels, myocardium, pericardium, heart valves and the conduction system. The diagnosis of these unique cardiac complications necessitates medical awareness and a high index of suspicion. Increased risk of advanced atherosclerosis plays a pivotal role in the development of cardiac diseases in systemic, rheumatic and autoimmune illnesses. Yet, other complex immune medicated mechanisms may contribute to the pathogenesis. Patients' optimal care requires coordination between the primary caregiver, the rheumatologist, immunologist and cardiologist. Screening for cardiovascular risk factors, recognition of high-risk patients and identification of subclinical cardiac conditions are of great importance. Moreover, regulation of inflammation, as well as abnormal immune responses and the initiation of early treatments should be the focus of patient management. A continuous attempt to identify novel therapeutic targets and change the natural history of the underlying disease and its cardiac manifestations is in progress. The book aims at providing the readers with a state of the art collection of up to date information regarding clinically important topics based on experts' perspectives. This book was a result of an extended coordinated collaboration of one-hundred and fifty-four distinguished scientists from thirty-one countries around the globe. - A review of common, as well as unusual (yet clinically significant) medical cardiac complications of prevalent rheumatic, autoimmune and inflammatory diseases. - Focuses on aspects of pathophysiological processes, clinical presentations, screening tests, prognostic implications and novel therapeutic approaches. - Presents an up-to-date "level of evidence and "strengths of recommendations for suggested therapies and reviews all randomized clinical trials, meta-analyses and other supporting published clinical findings.

Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Second Edition provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations in both the thrombotic and non-thrombotic manifestations of this important disease. Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy, and memory loss, and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, and from psychiatry to orthopedics. - Brings the reader up-to-date and allows easy access to individual topics in one place - Written by a respected panel of distinguished physicians/scientists actively involved in the field of Antiphospholipid Syndrome - Includes box summaries at the end of each chapter that highlight important topics - Gives up-to-date, basic knowledge and a modern approach to diagnosis and therapy - Provides a comprehensive review of this major disease - Includes information on treatment options available

In this book is found the information essential to diagnosing, managing and treating the lung complications of connective tissue diseases. This is a notoriously difficult area, which continues to puzzle clinicians, despite the fact that these disorders are increasingly frequent (as a result of longer survival in connective tissue disease). In separate chapters, the major connective tissue diseases are reviewed, with detailed discussion of a variety of lung abnormalities, including pleural disease, parenchymal lung disease and pulmonary vascular disease. There are also invaluable overviews of lung histological and CT appearances in these disorders, and a deeply insightful chapter on drug-induced lung disease in connective tissue disease. The emphasis in this book is on accuracy of evaluation and the construction of a logical management plan, based on disease severity and intrinsic progressiveness.

Not too long ago, it was thought that inflammation of blood vessels was the sole manifestation of systemic autoimmune diseases. Today, however, we know that disorders of coagulation, injuries to both neutrophils and endothelial cells, and certain lipids and amino acids are all intricately involved in the development of vascular disease. How are all

This volume brings together an international group of clinicians and clinical scientists to contribute to a state-of the-art review of the underlying pathogenic mechanisms, methods of clinical assessment, classification and diagnosis of renal disease, combined with a detailed overview of treatment strategies. An essential reference source for all those involved with the care of patients with renal involvement in systemic autoimmune disease, and for those contributing to research into the underlying pathogenic mechanisms in these disorders.